دورية أكاديمية
Model-informed precision dosing of beta-lactam antibiotics and ciprofloxacin in critically ill patients: a multicentre randomised clinical trial.
| العنوان: | Model-informed precision dosing of beta-lactam antibiotics and ciprofloxacin in critically ill patients: a multicentre randomised clinical trial. |
|---|---|
| المؤلفون: | Ewoldt TMJ; Department of Intensive Care Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands. t.ewoldt@erasmusmc.nl.; Department Hospital Pharmacy, Erasmus University Medical Center, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands. t.ewoldt@erasmusmc.nl.; Rotterdam Clinical Pharmacometrics Group, Rotterdam, The Netherlands. t.ewoldt@erasmusmc.nl., Abdulla A; Department Hospital Pharmacy, Erasmus University Medical Center, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.; Rotterdam Clinical Pharmacometrics Group, Rotterdam, The Netherlands., Rietdijk WJR; Department Hospital Pharmacy, Erasmus University Medical Center, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands., Muller AE; Rotterdam Clinical Pharmacometrics Group, Rotterdam, The Netherlands.; Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center, Rotterdam, The Netherlands.; Department of Medical Microbiology, Haaglanden Medical Center, The Hague, The Netherlands., de Winter BCM; Department Hospital Pharmacy, Erasmus University Medical Center, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.; Rotterdam Clinical Pharmacometrics Group, Rotterdam, The Netherlands., Hunfeld NGM; Department of Intensive Care Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.; Department Hospital Pharmacy, Erasmus University Medical Center, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands., Purmer IM; Department of Intensive Care Medicine, Haga Hospital, The Hague, The Netherlands., van Vliet P; Department of Intensive Care Medicine, Haaglanden Medical Center, The Hague, The Netherlands., Wils EJ; Department of Intensive Care Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.; Department of Intensive Care Medicine, Franciscus Gasthuis en Vlietland, Rotterdam, The Netherlands., Haringman J; Department of Intensive Care Medicine, Isala Hospital, Zwolle, The Netherlands., Draisma A; Department of Intensive Care Medicine, Groene Hart Hospital, Gouda, The Netherlands., Rijpstra TA; Department of Intensive Care Medicine, Amphia Hospital, Breda, The Netherlands., Karakus A; Department of Intensive Care Medicine, Diakonessenhuis, Utrecht, The Netherlands., Gommers D; Department of Intensive Care Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands., Endeman H; Department of Intensive Care Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands., Koch BCP; Department Hospital Pharmacy, Erasmus University Medical Center, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.; Rotterdam Clinical Pharmacometrics Group, Rotterdam, The Netherlands. |
| المصدر: | Intensive care medicine [Intensive Care Med] 2022 Dec; Vol. 48 (12), pp. 1760-1771. Date of Electronic Publication: 2022 Nov 09. |
| نوع المنشور: | Randomized Controlled Trial; Multicenter Study; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer Verlag Country of Publication: United States NLM ID: 7704851 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1238 (Electronic) Linking ISSN: 03424642 NLM ISO Abbreviation: Intensive Care Med Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: New York : Springer Verlag Original Publication: Berlin ; New York, Springer International. |
| مواضيع طبية MeSH: | Critical Illness*/therapy , beta-Lactams*/therapeutic use, Humans ; Middle Aged ; Ciprofloxacin/therapeutic use ; Intensive Care Units ; Anti-Bacterial Agents/therapeutic use ; Monobactams |
| مستخلص: | Purpose: Individualising drug dosing using model-informed precision dosing (MIPD) of beta-lactam antibiotics and ciprofloxacin has been proposed as an alternative to standard dosing to optimise antibiotic efficacy in critically ill patients. However, randomised clinical trials (RCT) on clinical outcomes have been lacking. Methods: This multicentre RCT, including patients admitted to the intensive care unit (ICU) who were treated with antibiotics, was conducted in eight hospitals in the Netherlands. Patients were randomised to MIPD with dose and interval adjustments based on monitoring serum drug levels (therapeutic drug monitoring) combined with pharmacometric modelling of beta-lactam antibiotics and ciprofloxacin. The primary outcome was ICU length of stay (LOS). Secondary outcomes were ICU mortality, hospital mortality, 28-day mortality, 6-month mortality, delta sequential organ failure assessment (SOFA) score, adverse events and target attainment. Results: In total, 388 (MIPD n = 189; standard dosing n = 199) patients were analysed (median age 64 [IQR 55-71]). We found no significant differences in ICU LOS between MIPD compared to standard dosing (10 MIPD vs 8 standard dosing; IRR = 1.16; 95% CI 0.96-1.41; p = 0.13). There was no significant difference in target attainment before intervention at day 1 (T1) (55.6% MIPD vs 60.9% standard dosing; p = 0.24) or at day 3 (T3) (59.5% vs 60.4%; p = 0.84). There were no significant differences in other secondary outcomes. Conclusions: We could not show a beneficial effect of MIPD of beta-lactam antibiotics and ciprofloxacin on ICU LOS in critically ill patients. Our data highlight the need to identify other approaches to dose optimisation. (© 2022. The Author(s).) |
| التعليقات: | Comment in: Intensive Care Med. 2023 Mar;49(3):324-326. (PMID: 36695835) |
| References: | Bassetti M, Rello J, Blasi F, Goossens H, Sotgiu G, Tavoschi L, Zasowski EJ, Arber MR, McCool R, Patterson JV, Longshaw CM, Lopes S, Manissero D, Nguyen ST, Tone K, Aliberti S (2020) Systematic review of the impact of appropriate versus inappropriate initial antibiotic therapy on outcomes of patients with severe bacterial infections. Int J Antimicrob Agents 56:106184. (PMID: 10.1016/j.ijantimicag.2020.10618433045353) Kollef MH, Shorr AF, Bassetti M, Timsit J-F, Micek ST, Michelson AP, Garnacho-Montero J (2021) Timing of antibiotic therapy in the ICU. Crit Care 25:360. (PMID: 10.1186/s13054-021-03787-z851827334654462) Axente C, Licker M, Moldovan R, Hogea E, Muntean D, Horhat F, Bedreag O, Sandesc D, Papurica M, Dugaesescu D, Voicu M, Baditoiu L (2017) Antimicrobial consumption, costs and resistance patterns: a two year prospective study in a Romanian intensive care unit. BMC Infect Dis 17:358. (PMID: 10.1186/s12879-017-2440-7544100428532467) Dulhunty JM, Webb SAR, Paterson DL, Bellomo R, Myburgh J, Roberts JA, Lipman J (2010) A survey of antibiotic prescribing practices in Australian and New Zealand intensive care units. Crit Care Resusc 12:162–170. (PMID: 21261573) Smith BS, Yogaratnam D, Levasseur-Franklin KE, Forni A, Fong J (2012) Introduction to drug pharmacokinetics in the critically III patient. Chest 141:1327–1336. (PMID: 10.1378/chest.11-139622553267) Abdulla A, Dijkstra A, Hunfeld NGM, Endeman H, Bahmany S, Ewoldt TMJ, Muller AE, van Gelder T, Gommers D, Koch BCP (2020) Failure of target attainment of beta-lactam antibiotics in critically ill patients and associated risk factors: a two-center prospective study (EXPAT). Crit Care 24:558. (PMID: 10.1186/s13054-020-03272-z749335832933574) Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, Kaukonen K-M, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Lipman J, Study D, Roberts JA, Lipman J, Starr T, Wallis SC, Paul SK, MargaritRibas A, De Waele JJ, De Crop L, Spapen H, Wauters J, Dugernier T, Jorens P, Dapper I, De Backer D, Taccone FS, Rello J, Ruano L, Afonso E, Alvarez-Lerma F, Gracia-Arnillas MP, Fernández F, Feijoo N, Bardolet N, Rovira A, Garro P, Colon D, Castillo C, Fernado J, Lopez MJ, Fernandez JL, Arribas AM, Teja JL, Ots E, Carlos Montejo J, Catalan M, Prieto I, Gonzalo G, Galvan B, Blasco MA, Meyer E, Del Nogal F, Vidaur L, Sebastian R, Garde PM, Martin Velasco MDM, Zaragoza Crespo R, Esperatti M, Torres A, Montravers P, Baldesi O, Dupont H, Mahjoub Y, Lasocki S, Constantin JM, Payen JF, Martin C, Albanese J, Malledant Y, Pottecher J, Lefrant J-Y, Jaber S, Joannes-Boyau O, Orban C, Ostermann M, McKenzie C, Berry W, Smith J, Lei K, Rubulotta F, Gordon A, Brett S, Stotz M, Templeton M, Rhodes A, Ebm C, Moran C, Kaukonen K-M, Pettilä V, Dimopoulos G, Koulenti D, Xristodoulou A, Theodorou V, Kouliatsis G, Sertaridou E, Anthopoulos G, Choutas G, Rantis T, Karatzas S, Balla M, Papanikolaou M, Myrianthefs P, Gavala A, Fildisis G, Koutsoukou A, Kyriakopoulou M, Petrochilou K, Kompoti M, Michalia M, Clouva-Molyvdas F-M, Gkiokas G, Nikolakopoulos F, Psychogiou V, Malliotakis P, Akoumianaki E, Lilitsis E, Koulouras V, Nakos G, Kalogirou M, Komnos A, Zafeiridis T, Chaintoutis C, Arvaniti K, Matamis D, Chaintoutis C, Kydona C, Gritsi-Gerogianni N, Giasnetsova T, Giannakou M, Soultati I, Chytas I, Antoniadou E, Antipa E, Lathyris D, Koukoubani T, Paraforou T, Spiropoulou K, Bekos V, Spring A, Kalatzi T, Nikolaou H, Laskou M, Strouvalis I, Aloizos S, Kapogiannis S, Soldatou O, Bassetti M, Adembri C, Villa G, Giarratano A, Maurizio Raineri S, Cortegiani A, Montalto F, Strano MT, Ranieri VM, Sandroni C, De Pascale G, Molin A, Pelosi P, Montagnani L, Urbino R, Mastromauro I, De Rosa FG, Ranieri VM, Cardoso T, Afonso S, Gonçalves-Pereira J, Baptista JP, Akova M, Özveren A (2014) DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 58:1072–1083. (PMID: 10.1093/cid/ciu02724429437) Abdulla A, Rogouti O, Hunfeld NGM, Endeman H, Dijkstra A, van Gelder T, Muller AE, de Winter BCM, Koch BCP (2020) Population pharmacokinetics and target attainment of ciprofloxacin in critically ill patients. Eur J Clin Pharmacol 76:957–967. (PMID: 10.1007/s00228-020-02873-5730603032307575) McKinnon PS, Paladino JA, Schentag JJ (2008) Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 31:345–351. (PMID: 10.1016/j.ijantimicag.2007.12.00918313273) Abdul-Aziz MH, Lipman J, Mouton JW, Hope WW, Roberts JA (2015) Applying pharmacokinetic/pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development. Semin Respir Crit Care Med 36:136–153. (PMID: 10.1055/s-0034-139849025643277) Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, Han C, Bisignano C, Rao P, Wool E, Johnson SC, Browne AJ, Chipeta MG, Fell F, Hackett S, Haines-Woodhouse G, KashefHamadani BH, Kumaran EAP, McManigal B, Agarwal R, Akech S, Albertson S, Amuasi J, Andrews J, Aravkin A, Ashley E, Bailey F, Baker S, Basnyat B, Bekker A, Bender R, Bethou A, Bielicki J, Boonkasidecha S, Bukosia J, Carvalheiro C, Castañeda-Orjuela C, Chansamouth V, Chaurasia S, Chiurchiù S, Chowdhury F, Cook AJ, Cooper B, Cressey TR, Criollo-Mora E, Cunningham M, Darboe S, Day NPJ, De Luca M, Dokova K, Dramowski A, Dunachie SJ, Eckmanns T, Eibach D, Emami A, Feasey N, Fisher-Pearson N, Forrest K, Garrett D, Gastmeier P, Giref AZ, Greer RC, Gupta V, Haller S, Haselbeck A, Hay SI, Holm M, Hopkins S, Iregbu KC, Jacobs J, Jarovsky D, Javanmardi F, Khorana M, Kissoon N, Kobeissi E, Kostyanev T, Krapp F, Krumkamp R, Kumar A, Kyu HH, Lim C, Limmathurotsakul D, Loftus MJ, Lunn M, Ma J, Mturi N, Munera-Huertas T, Musicha P, Mussi-Pinhata MM, Nakamura T, Nanavati R, Nangia S, Newton P, Ngoun C, Novotney A, Nwakanma D, Obiero CW, Olivas-Martinez A, Olliaro P, Ooko E, Ortiz-Brizuela E, Peleg AY, Perrone C, Plakkal N, Ponce-de-Leon A, Raad M, Ramdin T, Riddell A, Roberts T, Robotham JV, Roca A, Rudd KE, Russell N, Schnall J, Scott JAG, Shivamallappa M, Sifuentes-Osornio J, Steenkeste N, Stewardson AJ, Stoeva T, Tasak N, Thaiprakong A, Thwaites G, Turner C, Turner P, van Doorn HR, Velaphi S, Vongpradith A, Vu H, Walsh T, Waner S, Wangrangsimakul T, Wozniak T, Zheng P, Sartorius B, Lopez AD, Stergachis A, Moore C, Dolecek C, Naghavi M (2022) Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 399:629–655. (PMID: 10.1016/S0140-6736(21)02724-0) Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, Machado FR, McIntyre L, Ostermann M, Prescott HC, Schorr C, Simpson S, Wiersinga WJ, Alshamsi F, Angus DC, Arabi Y, Azevedo L, Beale R, Beilman G, Belley-Cote E, Burry L, Cecconi M, Centofanti J, Coz Yataco A, De Waele J, Dellinger RP, Doi K, Du B, Estenssoro E, Ferrer R, Gomersall C, Hodgson C, HylanderMøller M, Iwashyna T, Jacob S, Kleinpell R, Klompas M, Koh Y, Kumar A, Kwizera A, Lobo S, Masur H, McGloughlin S, Mehta S, Mehta Y, Mer M, Nunnally M, Oczkowski S, Osborn T, Papathanassoglou E, Perner A, Puskarich M, Roberts J, Schweickert W, Seckel M, Sevransky J, Sprung CL, Welte T, Zimmerman J, Levy M (2021) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med 49:1063–1143. (PMID: 10.1097/CCM.0000000000005337) Muller AE, Huttner B, Huttner A (2018) Therapeutic drug monitoring of beta-lactams and other antibiotics in the intensive care unit: which agents, which patients and which infections? Drugs 78:439–451. (PMID: 10.1007/s40265-018-0880-z29476349) Sime FB, Roberts MS, Tiong IS, Gardner JH, Lehman S, Peake SL, Hahn U, Warner MS, Roberts JA (2015) Can therapeutic drug monitoring optimize exposure to piperacillin in febrile neutropenic patients with haematological malignancies? A randomized controlled trial. J Antimicrob Chemother 70:2369–2375. (PMID: 10.1093/jac/dkv12325953805) De Waele JJ, Carrette S, Carlier M, Stove V, Boelens J, Claeys G, Leroux-Roels I, Hoste E, Depuydt P, Decruyenaere J, Verstraete AG (2014) Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial. Intensive Care Med 40:380–387. (PMID: 10.1007/s00134-013-3187-224356862) Tängdén T, Ramos Martín V, Felton TW, Nielsen EI, Marchand S, Brüggemann RJ, Bulitta JB, Bassetti M, Theuretzbacher U, Tsuji BT, Wareham DW, Friberg LE, De Waele JJ, Tam VH, Roberts JA, Infection Section for the European Society of Intensive Care Medicine tP, Pharmacodynamics Study Group of the European Society of Clinical M, Infectious Diseases tISoA-IP, the Critically Ill Patients Study Group of European Society of Clinical M, Infectious D (2017) The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections. Intensive Care Med 43:1021–1032. (PMID: 10.1007/s00134-017-4780-628409203) Wicha SG, Märtson A-G, Nielsen EI, Koch BCP, Friberg LE, Alffenaar J-W, Minichmayr IK, The International Society of Anti-Infective Pharmacology tPKPDsgotESoCMID (2021) From therapeutic drug monitoring to model-informed precision dosing for antibiotics. Clin Pharmacol Ther 109:928–941. (PMID: 10.1002/cpt.220233565627) Fratoni AJ, Nicolau DP, Kuti JL (2021) A guide to therapeutic drug monitoring of β-lactam antibiotics. Pharmacotherapy 41:220–233. (PMID: 10.1002/phar.250533480024) Abdulla A, Ewoldt TMJ, Hunfeld NGM, Muller AE, Rietdijk WJR, Polinder S, van Gelder T, Endeman H, Koch BCP (2020) The effect of therapeutic drug monitoring of beta-lactam and fluoroquinolones on clinical outcome in critically ill patients: the DOLPHIN trial protocol of a multi-centre randomised controlled trial. BMC Infect Dis 20:57. (PMID: 10.1186/s12879-020-4781-x696946231952493) Wittekamp BHJ, Oostdijk EAN, Cuthbertson BH, Brun-Buisson C, Bonten MJM (2020) Selective decontamination of the digestive tract (SDD) in critically ill patients: a narrative review. Intensive Care Med 46:343–349. (PMID: 10.1007/s00134-019-05883-931820032) SWAB Guidelines (2022) SWAB Guidelines. Stichting Werkgroep Antibioticabeleid. Committee ES (2021) MIC distributions and the setting of epidemiological cut-off (ECOFF) values. MIC distributions and the setting of epidemiological cut-off (ECOFF) values. EUCAST. Bahmany S, Abdulla A, Ewoldt TMJ, Oehlers PL, de Winter BCM, Koch BCP (2022) High-throughput analysis for the simultaneous quantification of nine beta-lactam antibiotics in human plasma by UPC2-MS/MS: method development, validation, and clinical application. J Pharm Biomed Anal 219:114904. (PMID: 10.1016/j.jpba.2022.11490435772234) Ewoldt TMJ, Abdulla A, Hunfeld NGM, Muller AE, Gommers D, Polinder S, Koch BCP, Endeman H (2022) Health care costs of target attainment for beta-lactam antibiotics in critically ill patients: a retrospective analysis of the EXPAT study. Ther Drug Monit 44:224–229. (PMID: 10.1097/FTD.000000000000089133770020) Hakkaart-van Roijen L, Van der Linden N, Bouwmans C, Kanters T, Tan S (2016) Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg. Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg. Zorginstituut Nederland. Hagel S, Bach F, Brenner T, Bracht H, Brinkmann A, Annecke T, Hohn A, Weigand M, Michels G, Kluge S, Nierhaus A, Jarczak D, König C, Weismann D, Frey O, Witzke D, Müller C, Bauer M, Kiehntopf M, Neugebauer S, Lehmann T, Roberts JA, Pletz MW, Braune A, Schmidt K, Motsch J, Pinder N, Richter D, Schlattmann P, von Ameln-Mayerhofer A, Schappacher M, Fuchs T, Röhr A, Kurlbaum M, Schreiner O, Hüter L, Gründling M, Angermair S, Deja M, Bloos F, Fiedler S, Chkirni H (2022) Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial. Intensive Care Med 48:311–321. (PMID: 10.1007/s00134-021-06609-6886635935106617) Machado AS, Oliveira MS, Sanches C, Silva Junior CVd, Gomez DS, Gemperli R, Santos SRCJ, Levin AS (2017) Clinical outcome and antimicrobial therapeutic drug monitoring for the treatment of infections in acute burn patients. Clin Ther 39:1649-1657.e1643. (PMID: 10.1016/j.clinthera.2017.06.00828705450) Wong G, Briscoe S, McWhinney B, Ally M, Ungerer J, Lipman J, Roberts JA (2018) Therapeutic drug monitoring of β-lactam antibiotics in the critically ill: direct measurement of unbound drug concentrations to achieve appropriate drug exposures. J Antimicrob Chemother 73:3087–3094. (PMID: 10.1093/jac/dky31430137377) Roger C, Louart B (2021) Beta-lactams toxicity in the intensive care unit: an underestimated collateral damage? Microorganisms 9:1505. (PMID: 10.3390/microorganisms9071505830632234361942) Guilhaumou R, Benaboud S, Bennis Y, Dahyot-Fizelier C, Dailly E, Gandia P, Goutelle S, Lefeuvre S, Mongardon N, Roger C, Scala-Bertola J, Lemaitre F, Garnier M (2019) Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d’Anesthésie et Réanimation-SFAR). Crit Care 23:104. (PMID: 10.1186/s13054-019-2378-9644123230925922) Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M (2006) Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock*. Crit Care Med 34:1589–1596. (PMID: 10.1097/01.CCM.0000217961.75225.E916625125) Dreesen E, Gijsen M, Elkayal O, Annaert P, Debaveye Y, Wauters J, Karlsson MO, Spriet I (2022) Ceftriaxone dosing based on the predicted probability of augmented renal clearance in critically ill patients with pneumonia. J Antimicrob Chemother. https://doi.org/10.1093/jac/dkac209. (PMID: 10.1093/jac/dkac20935815604) Yang N, Wang J, Xie Y, Ding J, Wu C, Liu J, Pei Q (2022) External evaluation of population pharmacokinetic models to inform precision dosing of meropenem in critically ill patients. Front Pharmacol 13:838205. (PMID: 10.3389/fphar.2022.838205915777135662716) Visser EWA, Yan J, van Ijzendoorn LJ, Prins MWJ (2018) Continuous biomarker monitoring by particle mobility sensing with single molecule resolution. Nat Commun 9:2541. (PMID: 10.1038/s41467-018-04802-8602619429959314) Ates HC, Roberts JA, Lipman J, Cass AEG, Urban GA, Dincer C (2020) On-Site Therapeutic Drug Monitoring. Trends Biotechnol 38:1262–1277. (PMID: 10.1016/j.tibtech.2020.03.00133058758) Abdulla A, Ewoldt TMJ, Purmer IM, Muller AE, Gommers D, Endeman H, Koch BCP (2021) A narrative review of predictors for β-lactam antibiotic exposure during empirical treatment in critically ill patients. Expert Opin Drug Metab Toxicol 17:359–368. (PMID: 10.1080/17425255.2021.187904933463382) Mouton JW, Muller AE, Canton R, Giske CG, Kahlmeter G, Turnidge J (2017) MIC-based dose adjustment: facts and fables. J Antimicrob Chemother 73:564–568. (PMID: 10.1093/jac/dkx427) |
| معلومات مُعتمدة: | MRace Erasmus Universitair Medisch Centrum Rotterdam; 848017008 Netherlands ZONMW_ ZonMw |
| فهرسة مساهمة: | Keywords: Beta-lactam antibiotics; Ciprofloxacin; Critically ill; Model-informed; Precision dosing |
| المشرفين على المادة: | 0 (beta-Lactams) 5E8K9I0O4U (Ciprofloxacin) 0 (Anti-Bacterial Agents) 0 (Monobactams) |
| تواريخ الأحداث: | Date Created: 20221109 Date Completed: 20221130 Latest Revision: 20230619 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC9645317 |
| DOI: | 10.1007/s00134-022-06921-9 |
| PMID: | 36350354 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1432-1238 |
|---|---|
| DOI: | 10.1007/s00134-022-06921-9 |